Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
NCT06069830Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of PD-1 Monoclonal Antibody in Extranodal NK/T-cell lymphoma (ENKTL) (3 cohorts), sponsored by Ruijin Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2023; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06069830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069830.